These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 29313067)
21. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501 [TBL] [Abstract][Full Text] [Related]
22. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209 [TBL] [Abstract][Full Text] [Related]
23. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. Le SB; Hailer MK; Buhrow S; Wang Q; Flatten K; Pediaditakis P; Bible KC; Lewis LD; Sausville EA; Pang YP; Ames MM; Lemasters JJ; Holmuhamedov EL; Kaufmann SH J Biol Chem; 2007 Mar; 282(12):8860-72. PubMed ID: 17213201 [TBL] [Abstract][Full Text] [Related]
25. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cai B; Lyu H; Huang J; Wang S; Lee CK; Gao C; Liu B Cancer Lett; 2013 Jul; 335(2):343-50. PubMed ID: 23459296 [TBL] [Abstract][Full Text] [Related]
26. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Chandra J; Hackbarth J; Le S; Loegering D; Bone N; Bruzek LM; Narayanan VL; Adjei AA; Kay NE; Tefferi A; Karp JE; Sausville EA; Kaufmann SH Blood; 2003 Dec; 102(13):4512-9. PubMed ID: 12920036 [TBL] [Abstract][Full Text] [Related]
27. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541 [TBL] [Abstract][Full Text] [Related]
28. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197 [TBL] [Abstract][Full Text] [Related]
30. Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1. Fer ND; Shoemaker RH; Monks A J Exp Clin Cancer Res; 2010 Jul; 29(1):91. PubMed ID: 20618971 [TBL] [Abstract][Full Text] [Related]
32. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. Thompson RC; Vardinogiannis I; Gilmore TD PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527 [TBL] [Abstract][Full Text] [Related]
33. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218 [TBL] [Abstract][Full Text] [Related]
34. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806 [TBL] [Abstract][Full Text] [Related]
35. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages. Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769 [TBL] [Abstract][Full Text] [Related]
36. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Bolden JE; Shi W; Jankowski K; Kan CY; Cluse L; Martin BP; MacKenzie KL; Smyth GK; Johnstone RW Cell Death Dis; 2013 Feb; 4(2):e519. PubMed ID: 23449455 [TBL] [Abstract][Full Text] [Related]
37. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Wang B; Lyu H; Pei S; Song D; Ni J; Liu B Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371 [TBL] [Abstract][Full Text] [Related]
38. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224 [TBL] [Abstract][Full Text] [Related]
39. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Zang Y; Kirk CJ; Johnson DE Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039 [TBL] [Abstract][Full Text] [Related]
40. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. Singh AK; Bishayee A; Pandey AK Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]